nodes	percent_of_prediction	percent_of_DWPC	metapath
Darifenacin—CYP2D6—Niacin—atherosclerosis	0.0964	0.169	CbGbCtD
Darifenacin—CYP2D6—Simvastatin—atherosclerosis	0.0762	0.134	CbGbCtD
Darifenacin—CYP2D6—Pravastatin—atherosclerosis	0.0746	0.131	CbGbCtD
Darifenacin—CYP2D6—Lovastatin—atherosclerosis	0.0746	0.131	CbGbCtD
Darifenacin—CYP3A4—Rosuvastatin—atherosclerosis	0.0521	0.0915	CbGbCtD
Darifenacin—CYP3A4—Ezetimibe—atherosclerosis	0.0521	0.0915	CbGbCtD
Darifenacin—CYP3A4—Simvastatin—atherosclerosis	0.0485	0.0851	CbGbCtD
Darifenacin—CYP3A4—Pravastatin—atherosclerosis	0.0474	0.0833	CbGbCtD
Darifenacin—CYP3A4—Lovastatin—atherosclerosis	0.0474	0.0833	CbGbCtD
Darifenacin—Gallbladder disorder—Ezetimibe—atherosclerosis	0.0182	0.0596	CcSEcCtD
Darifenacin—Respiratory tract infection—Pravastatin—atherosclerosis	0.0041	0.0134	CcSEcCtD
Darifenacin—Accidental injury—Rosuvastatin—atherosclerosis	0.00407	0.0133	CcSEcCtD
Darifenacin—Cough increased—Rosuvastatin—atherosclerosis	0.00393	0.0128	CcSEcCtD
Darifenacin—Accidental injury—Lovastatin—atherosclerosis	0.00345	0.0113	CcSEcCtD
Darifenacin—Cough increased—Niacin—atherosclerosis	0.00286	0.00935	CcSEcCtD
Darifenacin—Injury—Rosuvastatin—atherosclerosis	0.00284	0.00929	CcSEcCtD
Darifenacin—Vaginal inflammation—Niacin—atherosclerosis	0.00262	0.00856	CcSEcCtD
Darifenacin—Vaginal infection—Niacin—atherosclerosis	0.00247	0.00808	CcSEcCtD
Darifenacin—Injury—Lovastatin—atherosclerosis	0.00241	0.00787	CcSEcCtD
Darifenacin—Breast disorder—Rosuvastatin—atherosclerosis	0.00236	0.00772	CcSEcCtD
Darifenacin—Abnormal vision—Niacin—atherosclerosis	0.00228	0.00747	CcSEcCtD
Darifenacin—Influenza—Rosuvastatin—atherosclerosis	0.00226	0.00738	CcSEcCtD
Darifenacin—Bronchitis—Rosuvastatin—atherosclerosis	0.00217	0.0071	CcSEcCtD
Darifenacin—Injury—Pravastatin—atherosclerosis	0.00204	0.00666	CcSEcCtD
Darifenacin—Breast disorder—Ezetimibe—atherosclerosis	0.00196	0.00641	CcSEcCtD
Darifenacin—Urinary tract infection—Rosuvastatin—atherosclerosis	0.00196	0.0064	CcSEcCtD
Darifenacin—Aspartate aminotransferase increased—Ezetimibe—atherosclerosis	0.00195	0.00639	CcSEcCtD
Darifenacin—Alanine aminotransferase increased—Ezetimibe—atherosclerosis	0.00191	0.00626	CcSEcCtD
Darifenacin—Influenza—Lovastatin—atherosclerosis	0.00191	0.00625	CcSEcCtD
Darifenacin—Sinusitis—Rosuvastatin—atherosclerosis	0.00189	0.00617	CcSEcCtD
Darifenacin—Influenza—Ezetimibe—atherosclerosis	0.00188	0.00613	CcSEcCtD
Darifenacin—Face oedema—Niacin—atherosclerosis	0.00184	0.006	CcSEcCtD
Darifenacin—Rhinitis—Rosuvastatin—atherosclerosis	0.00181	0.00592	CcSEcCtD
Darifenacin—Urinary retention—Niacin—atherosclerosis	0.00181	0.00591	CcSEcCtD
Darifenacin—Pharyngitis—Rosuvastatin—atherosclerosis	0.00179	0.00586	CcSEcCtD
Darifenacin—Erectile dysfunction—Lovastatin—atherosclerosis	0.00176	0.00576	CcSEcCtD
Darifenacin—Dry skin—Niacin—atherosclerosis	0.00174	0.0057	CcSEcCtD
Darifenacin—Erectile dysfunction—Ezetimibe—atherosclerosis	0.00173	0.00565	CcSEcCtD
Darifenacin—Bronchitis—Simvastatin—atherosclerosis	0.00172	0.00563	CcSEcCtD
Darifenacin—Dry skin—Pravastatin—atherosclerosis	0.00172	0.00561	CcSEcCtD
Darifenacin—Infestation NOS—Ezetimibe—atherosclerosis	0.00167	0.00547	CcSEcCtD
Darifenacin—Infestation—Ezetimibe—atherosclerosis	0.00167	0.00547	CcSEcCtD
Darifenacin—Urinary tract infection—Lovastatin—atherosclerosis	0.00166	0.00542	CcSEcCtD
Darifenacin—Alanine aminotransferase increased—Pravastatin—atherosclerosis	0.00165	0.0054	CcSEcCtD
Darifenacin—Erectile dysfunction—Simvastatin—atherosclerosis	0.00165	0.00539	CcSEcCtD
Darifenacin—Influenza—Niacin—atherosclerosis	0.00164	0.00537	CcSEcCtD
Darifenacin—Influenza—Pravastatin—atherosclerosis	0.00162	0.00529	CcSEcCtD
Darifenacin—Sinusitis—Lovastatin—atherosclerosis	0.0016	0.00523	CcSEcCtD
Darifenacin—Mental disorder—Rosuvastatin—atherosclerosis	0.00158	0.00518	CcSEcCtD
Darifenacin—Bronchitis—Niacin—atherosclerosis	0.00158	0.00517	CcSEcCtD
Darifenacin—Sinusitis—Ezetimibe—atherosclerosis	0.00157	0.00513	CcSEcCtD
Darifenacin—Flatulence—Rosuvastatin—atherosclerosis	0.00155	0.00507	CcSEcCtD
Darifenacin—Erectile dysfunction—Niacin—atherosclerosis	0.00151	0.00495	CcSEcCtD
Darifenacin—Sinusitis—Simvastatin—atherosclerosis	0.0015	0.00489	CcSEcCtD
Darifenacin—Pharyngitis—Ezetimibe—atherosclerosis	0.00149	0.00487	CcSEcCtD
Darifenacin—Erectile dysfunction—Pravastatin—atherosclerosis	0.00149	0.00487	CcSEcCtD
Darifenacin—Oedema peripheral—Ezetimibe—atherosclerosis	0.00148	0.00484	CcSEcCtD
Darifenacin—Weight increased—Pravastatin—atherosclerosis	0.00147	0.00481	CcSEcCtD
Darifenacin—Erythema multiforme—Lovastatin—atherosclerosis	0.00145	0.00473	CcSEcCtD
Darifenacin—Angioedema—Rosuvastatin—atherosclerosis	0.00144	0.0047	CcSEcCtD
Darifenacin—Stomatitis—Niacin—atherosclerosis	0.00143	0.00467	CcSEcCtD
Darifenacin—Erythema multiforme—Ezetimibe—atherosclerosis	0.00142	0.00464	CcSEcCtD
Darifenacin—Sweating—Niacin—atherosclerosis	0.0014	0.00459	CcSEcCtD
Darifenacin—Urinary tract infection—Pravastatin—atherosclerosis	0.0014	0.00458	CcSEcCtD
Darifenacin—Cough—Rosuvastatin—atherosclerosis	0.00137	0.00449	CcSEcCtD
Darifenacin—Angiopathy—Ezetimibe—atherosclerosis	0.00136	0.00445	CcSEcCtD
Darifenacin—Erythema multiforme—Simvastatin—atherosclerosis	0.00135	0.00443	CcSEcCtD
Darifenacin—Mediastinal disorder—Ezetimibe—atherosclerosis	0.00135	0.00443	CcSEcCtD
Darifenacin—Sinusitis—Pravastatin—atherosclerosis	0.00135	0.00442	CcSEcCtD
Darifenacin—Arthralgia—Rosuvastatin—atherosclerosis	0.00134	0.00438	CcSEcCtD
Darifenacin—Rhinitis—Niacin—atherosclerosis	0.00132	0.00431	CcSEcCtD
Darifenacin—Mental disorder—Ezetimibe—atherosclerosis	0.00132	0.0043	CcSEcCtD
Darifenacin—Flatulence—Lovastatin—atherosclerosis	0.00131	0.00429	CcSEcCtD
Darifenacin—Dysgeusia—Lovastatin—atherosclerosis	0.00131	0.00427	CcSEcCtD
Darifenacin—Rhinitis—Pravastatin—atherosclerosis	0.0013	0.00424	CcSEcCtD
Darifenacin—Oedema peripheral—Niacin—atherosclerosis	0.0013	0.00424	CcSEcCtD
Darifenacin—Confusional state—Rosuvastatin—atherosclerosis	0.00129	0.00423	CcSEcCtD
Darifenacin—Back pain—Lovastatin—atherosclerosis	0.00129	0.00422	CcSEcCtD
Darifenacin—Flatulence—Ezetimibe—atherosclerosis	0.00129	0.00421	CcSEcCtD
Darifenacin—Pharyngitis—Pravastatin—atherosclerosis	0.00129	0.0042	CcSEcCtD
Darifenacin—Infection—Rosuvastatin—atherosclerosis	0.00128	0.00417	CcSEcCtD
Darifenacin—Visual impairment—Niacin—atherosclerosis	0.00127	0.00414	CcSEcCtD
Darifenacin—Back pain—Ezetimibe—atherosclerosis	0.00126	0.00413	CcSEcCtD
Darifenacin—Nervous system disorder—Rosuvastatin—atherosclerosis	0.00126	0.00412	CcSEcCtD
Darifenacin—Vision blurred—Lovastatin—atherosclerosis	0.00126	0.00411	CcSEcCtD
Darifenacin—Mental disorder—Simvastatin—atherosclerosis	0.00125	0.0041	CcSEcCtD
Darifenacin—Visual impairment—Pravastatin—atherosclerosis	0.00125	0.00408	CcSEcCtD
Darifenacin—Eye disorder—Niacin—atherosclerosis	0.00123	0.00402	CcSEcCtD
Darifenacin—Flatulence—Simvastatin—atherosclerosis	0.00123	0.00402	CcSEcCtD
Darifenacin—Erythema multiforme—Pravastatin—atherosclerosis	0.00122	0.004	CcSEcCtD
Darifenacin—Dysgeusia—Simvastatin—atherosclerosis	0.00122	0.00399	CcSEcCtD
Darifenacin—Angioedema—Lovastatin—atherosclerosis	0.00122	0.00398	CcSEcCtD
Darifenacin—Angioedema—Ezetimibe—atherosclerosis	0.00119	0.00391	CcSEcCtD
Darifenacin—Angiopathy—Niacin—atherosclerosis	0.00119	0.0039	CcSEcCtD
Darifenacin—Vision blurred—Simvastatin—atherosclerosis	0.00118	0.00384	CcSEcCtD
Darifenacin—Musculoskeletal discomfort—Rosuvastatin—atherosclerosis	0.00117	0.00382	CcSEcCtD
Darifenacin—Insomnia—Rosuvastatin—atherosclerosis	0.00116	0.0038	CcSEcCtD
Darifenacin—Palpitations—Ezetimibe—atherosclerosis	0.00116	0.00378	CcSEcCtD
Darifenacin—Cough—Ezetimibe—atherosclerosis	0.00114	0.00373	CcSEcCtD
Darifenacin—Angioedema—Simvastatin—atherosclerosis	0.00114	0.00372	CcSEcCtD
Darifenacin—Arthralgia—Lovastatin—atherosclerosis	0.00113	0.00371	CcSEcCtD
Darifenacin—Dyspepsia—Rosuvastatin—atherosclerosis	0.00113	0.00369	CcSEcCtD
Darifenacin—Hypertension—Ezetimibe—atherosclerosis	0.00113	0.00369	CcSEcCtD
Darifenacin—Flatulence—Niacin—atherosclerosis	0.00113	0.00369	CcSEcCtD
Darifenacin—Arthralgia—Ezetimibe—atherosclerosis	0.00111	0.00364	CcSEcCtD
Darifenacin—Flatulence—Pravastatin—atherosclerosis	0.00111	0.00363	CcSEcCtD
Darifenacin—Dry mouth—Lovastatin—atherosclerosis	0.00111	0.00363	CcSEcCtD
Darifenacin—Unspecified disorder of skin and subcutaneous tissue—Ezetimibe—atherosclerosis	0.00111	0.00361	CcSEcCtD
Darifenacin—Dysgeusia—Pravastatin—atherosclerosis	0.0011	0.00361	CcSEcCtD
Darifenacin—Fexofenadine—HRH1—atherosclerosis	0.0011	1	CrCbGaD
Darifenacin—Pain—Rosuvastatin—atherosclerosis	0.0011	0.00359	CcSEcCtD
Darifenacin—Constipation—Rosuvastatin—atherosclerosis	0.0011	0.00359	CcSEcCtD
Darifenacin—Confusional state—Lovastatin—atherosclerosis	0.0011	0.00359	CcSEcCtD
Darifenacin—Dry mouth—Ezetimibe—atherosclerosis	0.00109	0.00356	CcSEcCtD
Darifenacin—Anaphylactic shock—Lovastatin—atherosclerosis	0.00109	0.00356	CcSEcCtD
Darifenacin—Infection—Lovastatin—atherosclerosis	0.00108	0.00353	CcSEcCtD
Darifenacin—Vision blurred—Niacin—atherosclerosis	0.00108	0.00353	CcSEcCtD
Darifenacin—Confusional state—Ezetimibe—atherosclerosis	0.00108	0.00352	CcSEcCtD
Darifenacin—Anaphylactic shock—Ezetimibe—atherosclerosis	0.00107	0.00349	CcSEcCtD
Darifenacin—Vision blurred—Pravastatin—atherosclerosis	0.00106	0.00347	CcSEcCtD
Darifenacin—Arthralgia—Simvastatin—atherosclerosis	0.00106	0.00347	CcSEcCtD
Darifenacin—Infection—Ezetimibe—atherosclerosis	0.00106	0.00347	CcSEcCtD
Darifenacin—Feeling abnormal—Rosuvastatin—atherosclerosis	0.00106	0.00346	CcSEcCtD
Darifenacin—Gastrointestinal pain—Rosuvastatin—atherosclerosis	0.00105	0.00343	CcSEcCtD
Darifenacin—Nervous system disorder—Ezetimibe—atherosclerosis	0.00105	0.00342	CcSEcCtD
Darifenacin—Angioedema—Niacin—atherosclerosis	0.00105	0.00342	CcSEcCtD
Darifenacin—Skin disorder—Ezetimibe—atherosclerosis	0.00104	0.00339	CcSEcCtD
Darifenacin—Angioedema—Pravastatin—atherosclerosis	0.00103	0.00337	CcSEcCtD
Darifenacin—Syncope—Niacin—atherosclerosis	0.00103	0.00336	CcSEcCtD
Darifenacin—Confusional state—Simvastatin—atherosclerosis	0.00103	0.00335	CcSEcCtD
Darifenacin—Anaphylactic shock—Simvastatin—atherosclerosis	0.00102	0.00333	CcSEcCtD
Darifenacin—Oedema—Simvastatin—atherosclerosis	0.00102	0.00333	CcSEcCtD
Darifenacin—Abdominal pain—Rosuvastatin—atherosclerosis	0.00101	0.00332	CcSEcCtD
Darifenacin—Palpitations—Niacin—atherosclerosis	0.00101	0.00331	CcSEcCtD
Darifenacin—Infection—Simvastatin—atherosclerosis	0.00101	0.0033	CcSEcCtD
Darifenacin—Loss of consciousness—Niacin—atherosclerosis	0.00101	0.00329	CcSEcCtD
Darifenacin—Cough—Niacin—atherosclerosis	0.000999	0.00327	CcSEcCtD
Darifenacin—Musculoskeletal discomfort—Lovastatin—atherosclerosis	0.000991	0.00324	CcSEcCtD
Darifenacin—Insomnia—Lovastatin—atherosclerosis	0.000984	0.00322	CcSEcCtD
Darifenacin—Cough—Pravastatin—atherosclerosis	0.000984	0.00322	CcSEcCtD
Darifenacin—Arthralgia—Niacin—atherosclerosis	0.000975	0.00319	CcSEcCtD
Darifenacin—Hypertension—Pravastatin—atherosclerosis	0.000973	0.00318	CcSEcCtD
Darifenacin—Musculoskeletal discomfort—Ezetimibe—atherosclerosis	0.000972	0.00318	CcSEcCtD
Darifenacin—Dyspnoea—Lovastatin—atherosclerosis	0.00097	0.00317	CcSEcCtD
Darifenacin—Unspecified disorder of skin and subcutaneous tissue—Niacin—atherosclerosis	0.000968	0.00316	CcSEcCtD
Darifenacin—Insomnia—Ezetimibe—atherosclerosis	0.000965	0.00316	CcSEcCtD
Darifenacin—Arthralgia—Pravastatin—atherosclerosis	0.00096	0.00314	CcSEcCtD
Darifenacin—Dyspepsia—Lovastatin—atherosclerosis	0.000958	0.00313	CcSEcCtD
Darifenacin—Dry mouth—Niacin—atherosclerosis	0.000953	0.00312	CcSEcCtD
Darifenacin—Dyspnoea—Ezetimibe—atherosclerosis	0.000951	0.00311	CcSEcCtD
Darifenacin—Hypersensitivity—Rosuvastatin—atherosclerosis	0.000946	0.00309	CcSEcCtD
Darifenacin—Dyspepsia—Ezetimibe—atherosclerosis	0.000939	0.00307	CcSEcCtD
Darifenacin—Anaphylactic shock—Niacin—atherosclerosis	0.000934	0.00305	CcSEcCtD
Darifenacin—Oedema—Niacin—atherosclerosis	0.000934	0.00305	CcSEcCtD
Darifenacin—Pain—Lovastatin—atherosclerosis	0.00093	0.00304	CcSEcCtD
Darifenacin—Constipation—Lovastatin—atherosclerosis	0.00093	0.00304	CcSEcCtD
Darifenacin—Confusional state—Pravastatin—atherosclerosis	0.000928	0.00303	CcSEcCtD
Darifenacin—Musculoskeletal discomfort—Simvastatin—atherosclerosis	0.000927	0.00303	CcSEcCtD
Darifenacin—Gastrointestinal disorder—Ezetimibe—atherosclerosis	0.000921	0.00301	CcSEcCtD
Darifenacin—Asthenia—Rosuvastatin—atherosclerosis	0.000921	0.00301	CcSEcCtD
Darifenacin—Insomnia—Simvastatin—atherosclerosis	0.00092	0.00301	CcSEcCtD
Darifenacin—Anaphylactic shock—Pravastatin—atherosclerosis	0.00092	0.00301	CcSEcCtD
Darifenacin—Oedema—Pravastatin—atherosclerosis	0.00092	0.00301	CcSEcCtD
Darifenacin—Shock—Niacin—atherosclerosis	0.000919	0.00301	CcSEcCtD
Darifenacin—Infection—Pravastatin—atherosclerosis	0.000914	0.00299	CcSEcCtD
Darifenacin—Constipation—Ezetimibe—atherosclerosis	0.000912	0.00298	CcSEcCtD
Darifenacin—Pain—Ezetimibe—atherosclerosis	0.000912	0.00298	CcSEcCtD
Darifenacin—Tachycardia—Niacin—atherosclerosis	0.000912	0.00298	CcSEcCtD
Darifenacin—Pruritus—Rosuvastatin—atherosclerosis	0.000908	0.00297	CcSEcCtD
Darifenacin—Skin disorder—Niacin—atherosclerosis	0.000908	0.00297	CcSEcCtD
Darifenacin—Dyspnoea—Simvastatin—atherosclerosis	0.000907	0.00297	CcSEcCtD
Darifenacin—Hyperhidrosis—Niacin—atherosclerosis	0.000903	0.00295	CcSEcCtD
Darifenacin—Feeling abnormal—Lovastatin—atherosclerosis	0.000896	0.00293	CcSEcCtD
Darifenacin—Dyspepsia—Simvastatin—atherosclerosis	0.000896	0.00293	CcSEcCtD
Darifenacin—Gastrointestinal pain—Lovastatin—atherosclerosis	0.00089	0.00291	CcSEcCtD
Darifenacin—Hyperhidrosis—Pravastatin—atherosclerosis	0.000889	0.00291	CcSEcCtD
Darifenacin—Feeling abnormal—Ezetimibe—atherosclerosis	0.000879	0.00287	CcSEcCtD
Darifenacin—Gastrointestinal disorder—Simvastatin—atherosclerosis	0.000878	0.00287	CcSEcCtD
Darifenacin—Diarrhoea—Rosuvastatin—atherosclerosis	0.000878	0.00287	CcSEcCtD
Darifenacin—Gastrointestinal pain—Ezetimibe—atherosclerosis	0.000873	0.00285	CcSEcCtD
Darifenacin—Constipation—Simvastatin—atherosclerosis	0.00087	0.00284	CcSEcCtD
Darifenacin—Pain—Simvastatin—atherosclerosis	0.00087	0.00284	CcSEcCtD
Darifenacin—Abdominal pain—Lovastatin—atherosclerosis	0.00086	0.00281	CcSEcCtD
Darifenacin—Musculoskeletal discomfort—Niacin—atherosclerosis	0.000851	0.00278	CcSEcCtD
Darifenacin—Dizziness—Rosuvastatin—atherosclerosis	0.000849	0.00278	CcSEcCtD
Darifenacin—Insomnia—Niacin—atherosclerosis	0.000845	0.00276	CcSEcCtD
Darifenacin—Abdominal pain—Ezetimibe—atherosclerosis	0.000844	0.00276	CcSEcCtD
Darifenacin—Feeling abnormal—Simvastatin—atherosclerosis	0.000839	0.00274	CcSEcCtD
Darifenacin—Musculoskeletal discomfort—Pravastatin—atherosclerosis	0.000838	0.00274	CcSEcCtD
Darifenacin—Dyspnoea—Niacin—atherosclerosis	0.000833	0.00272	CcSEcCtD
Darifenacin—Gastrointestinal pain—Simvastatin—atherosclerosis	0.000832	0.00272	CcSEcCtD
Darifenacin—Insomnia—Pravastatin—atherosclerosis	0.000832	0.00272	CcSEcCtD
Darifenacin—Somnolence—Niacin—atherosclerosis	0.000831	0.00272	CcSEcCtD
Darifenacin—Dyspepsia—Niacin—atherosclerosis	0.000822	0.00269	CcSEcCtD
Darifenacin—Dyspnoea—Pravastatin—atherosclerosis	0.00082	0.00268	CcSEcCtD
Darifenacin—Dyspepsia—Pravastatin—atherosclerosis	0.00081	0.00265	CcSEcCtD
Darifenacin—Rash—Rosuvastatin—atherosclerosis	0.000809	0.00265	CcSEcCtD
Darifenacin—Dermatitis—Rosuvastatin—atherosclerosis	0.000809	0.00264	CcSEcCtD
Darifenacin—Gastrointestinal disorder—Niacin—atherosclerosis	0.000807	0.00264	CcSEcCtD
Darifenacin—Abdominal pain—Simvastatin—atherosclerosis	0.000804	0.00263	CcSEcCtD
Darifenacin—Headache—Rosuvastatin—atherosclerosis	0.000804	0.00263	CcSEcCtD
Darifenacin—Hypersensitivity—Lovastatin—atherosclerosis	0.000802	0.00262	CcSEcCtD
Darifenacin—Pain—Niacin—atherosclerosis	0.000799	0.00261	CcSEcCtD
Darifenacin—Pain—Pravastatin—atherosclerosis	0.000787	0.00257	CcSEcCtD
Darifenacin—Constipation—Pravastatin—atherosclerosis	0.000787	0.00257	CcSEcCtD
Darifenacin—Hypersensitivity—Ezetimibe—atherosclerosis	0.000786	0.00257	CcSEcCtD
Darifenacin—Asthenia—Lovastatin—atherosclerosis	0.000781	0.00255	CcSEcCtD
Darifenacin—Pruritus—Lovastatin—atherosclerosis	0.00077	0.00252	CcSEcCtD
Darifenacin—Asthenia—Ezetimibe—atherosclerosis	0.000766	0.0025	CcSEcCtD
Darifenacin—Gastrointestinal pain—Niacin—atherosclerosis	0.000764	0.0025	CcSEcCtD
Darifenacin—Nausea—Rosuvastatin—atherosclerosis	0.000762	0.00249	CcSEcCtD
Darifenacin—Feeling abnormal—Pravastatin—atherosclerosis	0.000758	0.00248	CcSEcCtD
Darifenacin—Pruritus—Ezetimibe—atherosclerosis	0.000755	0.00247	CcSEcCtD
Darifenacin—Gastrointestinal pain—Pravastatin—atherosclerosis	0.000752	0.00246	CcSEcCtD
Darifenacin—Hypersensitivity—Simvastatin—atherosclerosis	0.00075	0.00245	CcSEcCtD
Darifenacin—Diarrhoea—Lovastatin—atherosclerosis	0.000744	0.00243	CcSEcCtD
Darifenacin—Abdominal pain—Niacin—atherosclerosis	0.000739	0.00241	CcSEcCtD
Darifenacin—Asthenia—Simvastatin—atherosclerosis	0.00073	0.00239	CcSEcCtD
Darifenacin—Diarrhoea—Ezetimibe—atherosclerosis	0.00073	0.00239	CcSEcCtD
Darifenacin—Abdominal pain—Pravastatin—atherosclerosis	0.000727	0.00238	CcSEcCtD
Darifenacin—Pruritus—Simvastatin—atherosclerosis	0.00072	0.00235	CcSEcCtD
Darifenacin—Dizziness—Lovastatin—atherosclerosis	0.000719	0.00235	CcSEcCtD
Darifenacin—Dizziness—Ezetimibe—atherosclerosis	0.000706	0.00231	CcSEcCtD
Darifenacin—Diarrhoea—Simvastatin—atherosclerosis	0.000696	0.00228	CcSEcCtD
Darifenacin—Vomiting—Lovastatin—atherosclerosis	0.000692	0.00226	CcSEcCtD
Darifenacin—Hypersensitivity—Niacin—atherosclerosis	0.000688	0.00225	CcSEcCtD
Darifenacin—Rash—Lovastatin—atherosclerosis	0.000686	0.00224	CcSEcCtD
Darifenacin—Dermatitis—Lovastatin—atherosclerosis	0.000685	0.00224	CcSEcCtD
Darifenacin—Headache—Lovastatin—atherosclerosis	0.000682	0.00223	CcSEcCtD
Darifenacin—Vomiting—Ezetimibe—atherosclerosis	0.000678	0.00222	CcSEcCtD
Darifenacin—Hypersensitivity—Pravastatin—atherosclerosis	0.000678	0.00222	CcSEcCtD
Darifenacin—Dizziness—Simvastatin—atherosclerosis	0.000673	0.0022	CcSEcCtD
Darifenacin—Rash—Ezetimibe—atherosclerosis	0.000673	0.0022	CcSEcCtD
Darifenacin—Dermatitis—Ezetimibe—atherosclerosis	0.000672	0.0022	CcSEcCtD
Darifenacin—Asthenia—Niacin—atherosclerosis	0.00067	0.00219	CcSEcCtD
Darifenacin—Headache—Ezetimibe—atherosclerosis	0.000668	0.00219	CcSEcCtD
Darifenacin—Pruritus—Niacin—atherosclerosis	0.000661	0.00216	CcSEcCtD
Darifenacin—Asthenia—Pravastatin—atherosclerosis	0.00066	0.00216	CcSEcCtD
Darifenacin—Pruritus—Pravastatin—atherosclerosis	0.000651	0.00213	CcSEcCtD
Darifenacin—Vomiting—Simvastatin—atherosclerosis	0.000647	0.00212	CcSEcCtD
Darifenacin—Nausea—Lovastatin—atherosclerosis	0.000646	0.00211	CcSEcCtD
Darifenacin—Rash—Simvastatin—atherosclerosis	0.000642	0.0021	CcSEcCtD
Darifenacin—Dermatitis—Simvastatin—atherosclerosis	0.000641	0.0021	CcSEcCtD
Darifenacin—Diarrhoea—Niacin—atherosclerosis	0.000639	0.00209	CcSEcCtD
Darifenacin—Headache—Simvastatin—atherosclerosis	0.000637	0.00208	CcSEcCtD
Darifenacin—Nausea—Ezetimibe—atherosclerosis	0.000634	0.00207	CcSEcCtD
Darifenacin—Diarrhoea—Pravastatin—atherosclerosis	0.000629	0.00206	CcSEcCtD
Darifenacin—Dizziness—Niacin—atherosclerosis	0.000618	0.00202	CcSEcCtD
Darifenacin—Dizziness—Pravastatin—atherosclerosis	0.000608	0.00199	CcSEcCtD
Darifenacin—Nausea—Simvastatin—atherosclerosis	0.000604	0.00198	CcSEcCtD
Darifenacin—Vomiting—Niacin—atherosclerosis	0.000594	0.00194	CcSEcCtD
Darifenacin—Rash—Niacin—atherosclerosis	0.000589	0.00193	CcSEcCtD
Darifenacin—Dermatitis—Niacin—atherosclerosis	0.000589	0.00192	CcSEcCtD
Darifenacin—Headache—Niacin—atherosclerosis	0.000585	0.00191	CcSEcCtD
Darifenacin—Vomiting—Pravastatin—atherosclerosis	0.000585	0.00191	CcSEcCtD
Darifenacin—Rash—Pravastatin—atherosclerosis	0.00058	0.0019	CcSEcCtD
Darifenacin—Dermatitis—Pravastatin—atherosclerosis	0.00058	0.00189	CcSEcCtD
Darifenacin—Headache—Pravastatin—atherosclerosis	0.000576	0.00188	CcSEcCtD
Darifenacin—Nausea—Niacin—atherosclerosis	0.000555	0.00181	CcSEcCtD
Darifenacin—Nausea—Pravastatin—atherosclerosis	0.000546	0.00179	CcSEcCtD
Darifenacin—CHRM3—Signaling by GPCR—CCL2—atherosclerosis	2.5e-05	0.000202	CbGpPWpGaD
Darifenacin—CHRM4—Signaling Pathways—ESR1—atherosclerosis	2.49e-05	0.000201	CbGpPWpGaD
Darifenacin—CHRM1—Signaling Pathways—PLG—atherosclerosis	2.49e-05	0.000201	CbGpPWpGaD
Darifenacin—CHRM3—Signaling Pathways—PLG—atherosclerosis	2.48e-05	0.0002	CbGpPWpGaD
Darifenacin—CHRM5—Signaling Pathways—CAV1—atherosclerosis	2.48e-05	0.0002	CbGpPWpGaD
Darifenacin—CHRM2—Signaling by GPCR—CCL2—atherosclerosis	2.47e-05	0.0002	CbGpPWpGaD
Darifenacin—CHRM5—Signaling Pathways—APOA1—atherosclerosis	2.47e-05	0.0002	CbGpPWpGaD
Darifenacin—CYP2D6—Metabolism—NAMPT—atherosclerosis	2.47e-05	0.0002	CbGpPWpGaD
Darifenacin—CHRM4—Signaling Pathways—F2—atherosclerosis	2.46e-05	0.000199	CbGpPWpGaD
Darifenacin—CYP3A4—Metabolism—APOA4—atherosclerosis	2.46e-05	0.000199	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—PLG—atherosclerosis	2.46e-05	0.000199	CbGpPWpGaD
Darifenacin—CYP2D6—Metabolism—LIPC—atherosclerosis	2.45e-05	0.000198	CbGpPWpGaD
Darifenacin—CHRM3—Metabolism—GPX1—atherosclerosis	2.44e-05	0.000197	CbGpPWpGaD
Darifenacin—CYP2D6—Metabolism—APOC3—atherosclerosis	2.44e-05	0.000197	CbGpPWpGaD
Darifenacin—CYP2D6—Metabolism—LDLR—atherosclerosis	2.42e-05	0.000196	CbGpPWpGaD
Darifenacin—CYP3A4—Metabolism—CYP7A1—atherosclerosis	2.42e-05	0.000195	CbGpPWpGaD
Darifenacin—CHRM5—Signaling Pathways—ESR1—atherosclerosis	2.39e-05	0.000193	CbGpPWpGaD
Darifenacin—CHRM3—Metabolism—CD36—atherosclerosis	2.38e-05	0.000192	CbGpPWpGaD
Darifenacin—CYP2D6—Metabolism—CETP—atherosclerosis	2.37e-05	0.000191	CbGpPWpGaD
Darifenacin—CHRM5—Signaling Pathways—F2—atherosclerosis	2.36e-05	0.000191	CbGpPWpGaD
Darifenacin—CHRM1—Signaling Pathways—SOCS3—atherosclerosis	2.36e-05	0.00019	CbGpPWpGaD
Darifenacin—CHRM4—Signaling Pathways—PIK3CG—atherosclerosis	2.36e-05	0.00019	CbGpPWpGaD
Darifenacin—CHRM3—Signaling Pathways—SOCS3—atherosclerosis	2.35e-05	0.00019	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—SOCS3—atherosclerosis	2.33e-05	0.000188	CbGpPWpGaD
Darifenacin—CHRM1—Signaling Pathways—MMP3—atherosclerosis	2.28e-05	0.000184	CbGpPWpGaD
Darifenacin—CHRM3—Signaling Pathways—MMP3—atherosclerosis	2.27e-05	0.000183	CbGpPWpGaD
Darifenacin—CYP2D6—Metabolism—SCARB1—atherosclerosis	2.27e-05	0.000183	CbGpPWpGaD
Darifenacin—CHRM1—Signaling Pathways—IGF2—atherosclerosis	2.27e-05	0.000183	CbGpPWpGaD
Darifenacin—CHRM3—Signaling Pathways—IGF2—atherosclerosis	2.26e-05	0.000183	CbGpPWpGaD
Darifenacin—CHRM4—Signaling by GPCR—MAPK3—atherosclerosis	2.26e-05	0.000182	CbGpPWpGaD
Darifenacin—CHRM5—Signaling Pathways—PIK3CG—atherosclerosis	2.26e-05	0.000182	CbGpPWpGaD
Darifenacin—CHRM3—Metabolism—MTHFR—atherosclerosis	2.25e-05	0.000182	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—MMP3—atherosclerosis	2.25e-05	0.000182	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—IGF2—atherosclerosis	2.24e-05	0.000181	CbGpPWpGaD
Darifenacin—CYP3A4—Metabolism—CYP27A1—atherosclerosis	2.23e-05	0.00018	CbGpPWpGaD
Darifenacin—CHRM4—Signaling Pathways—INS—atherosclerosis	2.23e-05	0.00018	CbGpPWpGaD
Darifenacin—CHRM3—Metabolism—PPARA—atherosclerosis	2.21e-05	0.000179	CbGpPWpGaD
Darifenacin—CHRM1—Signaling Pathways—APOB—atherosclerosis	2.2e-05	0.000178	CbGpPWpGaD
Darifenacin—CHRM4—Signaling Pathways—CCL2—atherosclerosis	2.19e-05	0.000177	CbGpPWpGaD
Darifenacin—CHRM3—Signaling Pathways—APOB—atherosclerosis	2.19e-05	0.000177	CbGpPWpGaD
Darifenacin—CHRM1—GPCR downstream signaling—CXCL8—atherosclerosis	2.18e-05	0.000176	CbGpPWpGaD
Darifenacin—CHRM3—GPCR downstream signaling—CXCL8—atherosclerosis	2.17e-05	0.000176	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—APOB—atherosclerosis	2.17e-05	0.000176	CbGpPWpGaD
Darifenacin—CHRM1—Signaling Pathways—EDN1—atherosclerosis	2.17e-05	0.000175	CbGpPWpGaD
Darifenacin—CHRM5—Signaling by GPCR—MAPK3—atherosclerosis	2.16e-05	0.000175	CbGpPWpGaD
Darifenacin—CHRM3—Signaling Pathways—EDN1—atherosclerosis	2.16e-05	0.000174	CbGpPWpGaD
Darifenacin—CHRM4—Signaling Pathways—IGF1—atherosclerosis	2.16e-05	0.000174	CbGpPWpGaD
Darifenacin—CHRM2—GPCR downstream signaling—CXCL8—atherosclerosis	2.15e-05	0.000174	CbGpPWpGaD
Darifenacin—CHRM1—Signaling Pathways—CCL5—atherosclerosis	2.15e-05	0.000174	CbGpPWpGaD
Darifenacin—CHRM3—Metabolism—AGT—atherosclerosis	2.14e-05	0.000173	CbGpPWpGaD
Darifenacin—CHRM3—Signaling Pathways—CCL5—atherosclerosis	2.14e-05	0.000173	CbGpPWpGaD
Darifenacin—CYP2D6—Metabolism—HMGCR—atherosclerosis	2.14e-05	0.000173	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—EDN1—atherosclerosis	2.14e-05	0.000173	CbGpPWpGaD
Darifenacin—CHRM5—Signaling Pathways—INS—atherosclerosis	2.14e-05	0.000173	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—CCL5—atherosclerosis	2.12e-05	0.000171	CbGpPWpGaD
Darifenacin—CYP3A4—Metabolism—PLA2G2A—atherosclerosis	2.12e-05	0.000171	CbGpPWpGaD
Darifenacin—CYP3A4—Metabolism—APOA2—atherosclerosis	2.12e-05	0.000171	CbGpPWpGaD
Darifenacin—CYP3A4—Metabolism—ALOX5AP—atherosclerosis	2.12e-05	0.000171	CbGpPWpGaD
Darifenacin—CYP3A4—Metabolism—ALOX15—atherosclerosis	2.12e-05	0.000171	CbGpPWpGaD
Darifenacin—CHRM5—Signaling Pathways—CCL2—atherosclerosis	2.1e-05	0.00017	CbGpPWpGaD
Darifenacin—CHRM1—Signaling Pathways—LPL—atherosclerosis	2.1e-05	0.00017	CbGpPWpGaD
Darifenacin—CHRM3—Metabolism—APOE—atherosclerosis	2.1e-05	0.00017	CbGpPWpGaD
Darifenacin—CHRM3—Signaling Pathways—LPL—atherosclerosis	2.09e-05	0.000169	CbGpPWpGaD
Darifenacin—CYP3A4—Metabolism—ABCG5—atherosclerosis	2.09e-05	0.000169	CbGpPWpGaD
Darifenacin—CHRM3—Metabolism—CAV1—atherosclerosis	2.08e-05	0.000168	CbGpPWpGaD
Darifenacin—CHRM3—Metabolism—APOA1—atherosclerosis	2.08e-05	0.000168	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—LPL—atherosclerosis	2.07e-05	0.000168	CbGpPWpGaD
Darifenacin—CHRM5—Signaling Pathways—IGF1—atherosclerosis	2.07e-05	0.000167	CbGpPWpGaD
Darifenacin—CHRM4—Signaling Pathways—SERPINE1—atherosclerosis	2.05e-05	0.000166	CbGpPWpGaD
Darifenacin—CHRM1—Signaling Pathways—PRKCG—atherosclerosis	2.04e-05	0.000165	CbGpPWpGaD
Darifenacin—CHRM3—Signaling Pathways—PRKCG—atherosclerosis	2.04e-05	0.000165	CbGpPWpGaD
Darifenacin—CYP3A4—Metabolism—LPA—atherosclerosis	2.02e-05	0.000163	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—PRKCG—atherosclerosis	2.02e-05	0.000163	CbGpPWpGaD
Darifenacin—CHRM1—Signaling Pathways—SPP1—atherosclerosis	1.99e-05	0.000161	CbGpPWpGaD
Darifenacin—CHRM3—Signaling Pathways—SPP1—atherosclerosis	1.98e-05	0.00016	CbGpPWpGaD
Darifenacin—CHRM1—Signaling by GPCR—CXCL8—atherosclerosis	1.98e-05	0.00016	CbGpPWpGaD
Darifenacin—CHRM3—Signaling by GPCR—CXCL8—atherosclerosis	1.97e-05	0.00016	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—SPP1—atherosclerosis	1.96e-05	0.000159	CbGpPWpGaD
Darifenacin—CHRM5—Signaling Pathways—SERPINE1—atherosclerosis	1.96e-05	0.000159	CbGpPWpGaD
Darifenacin—CHRM4—Signaling Pathways—NOS3—atherosclerosis	1.96e-05	0.000158	CbGpPWpGaD
Darifenacin—CYP3A4—Metabolism—BGN—atherosclerosis	1.96e-05	0.000158	CbGpPWpGaD
Darifenacin—CHRM2—Signaling by GPCR—CXCL8—atherosclerosis	1.96e-05	0.000158	CbGpPWpGaD
Darifenacin—CYP3A4—Metabolism—APOA5—atherosclerosis	1.94e-05	0.000156	CbGpPWpGaD
Darifenacin—CYP2D6—Metabolism—ABCA1—atherosclerosis	1.91e-05	0.000154	CbGpPWpGaD
Darifenacin—CHRM3—Metabolism—PIK3CG—atherosclerosis	1.89e-05	0.000153	CbGpPWpGaD
Darifenacin—CHRM5—Signaling Pathways—NOS3—atherosclerosis	1.87e-05	0.000151	CbGpPWpGaD
Darifenacin—CYP3A4—Metabolism—PLA2G1B—atherosclerosis	1.86e-05	0.000151	CbGpPWpGaD
Darifenacin—CHRM1—Signaling Pathways—PDGFB—atherosclerosis	1.84e-05	0.000149	CbGpPWpGaD
Darifenacin—CHRM3—Signaling Pathways—PDGFB—atherosclerosis	1.84e-05	0.000148	CbGpPWpGaD
Darifenacin—CHRM3—Metabolism—PPARG—atherosclerosis	1.83e-05	0.000148	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—PDGFB—atherosclerosis	1.82e-05	0.000147	CbGpPWpGaD
Darifenacin—CYP3A4—Metabolism—ALOX5—atherosclerosis	1.8e-05	0.000145	CbGpPWpGaD
Darifenacin—CHRM1—Signaling Pathways—AGT—atherosclerosis	1.8e-05	0.000145	CbGpPWpGaD
Darifenacin—CHRM3—Metabolism—INS—atherosclerosis	1.79e-05	0.000145	CbGpPWpGaD
Darifenacin—CHRM3—Signaling Pathways—AGT—atherosclerosis	1.79e-05	0.000145	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—AGT—atherosclerosis	1.77e-05	0.000143	CbGpPWpGaD
Darifenacin—CHRM1—Signaling Pathways—LEP—atherosclerosis	1.76e-05	0.000142	CbGpPWpGaD
Darifenacin—CHRM1—Signaling Pathways—APOE—atherosclerosis	1.76e-05	0.000142	CbGpPWpGaD
Darifenacin—CHRM3—Signaling Pathways—LEP—atherosclerosis	1.76e-05	0.000142	CbGpPWpGaD
Darifenacin—CHRM3—Signaling Pathways—APOE—atherosclerosis	1.76e-05	0.000142	CbGpPWpGaD
Darifenacin—CHRM1—Signaling Pathways—CAV1—atherosclerosis	1.74e-05	0.000141	CbGpPWpGaD
Darifenacin—CHRM1—Signaling Pathways—APOA1—atherosclerosis	1.74e-05	0.000141	CbGpPWpGaD
Darifenacin—CHRM3—Signaling Pathways—CAV1—atherosclerosis	1.74e-05	0.000141	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—LEP—atherosclerosis	1.74e-05	0.00014	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—APOE—atherosclerosis	1.74e-05	0.00014	CbGpPWpGaD
Darifenacin—CHRM4—Signaling Pathways—CXCL8—atherosclerosis	1.74e-05	0.00014	CbGpPWpGaD
Darifenacin—CHRM3—Signaling Pathways—APOA1—atherosclerosis	1.74e-05	0.00014	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—CAV1—atherosclerosis	1.72e-05	0.000139	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—APOA1—atherosclerosis	1.72e-05	0.000139	CbGpPWpGaD
Darifenacin—CHRM1—Signaling Pathways—ESR1—atherosclerosis	1.68e-05	0.000136	CbGpPWpGaD
Darifenacin—CHRM4—GPCR downstream signaling—AKT1—atherosclerosis	1.68e-05	0.000135	CbGpPWpGaD
Darifenacin—CHRM3—Signaling Pathways—ESR1—atherosclerosis	1.68e-05	0.000135	CbGpPWpGaD
Darifenacin—CHRM5—Signaling Pathways—CXCL8—atherosclerosis	1.66e-05	0.000134	CbGpPWpGaD
Darifenacin—CHRM1—Signaling Pathways—F2—atherosclerosis	1.66e-05	0.000134	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—ESR1—atherosclerosis	1.66e-05	0.000134	CbGpPWpGaD
Darifenacin—CHRM3—Signaling Pathways—F2—atherosclerosis	1.66e-05	0.000134	CbGpPWpGaD
Darifenacin—CHRM4—Signaling by GPCR—IL6—atherosclerosis	1.65e-05	0.000133	CbGpPWpGaD
Darifenacin—CHRM3—Metabolism—ALB—atherosclerosis	1.64e-05	0.000133	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—F2—atherosclerosis	1.64e-05	0.000132	CbGpPWpGaD
Darifenacin—CYP2D6—Metabolism—HMOX1—atherosclerosis	1.64e-05	0.000132	CbGpPWpGaD
Darifenacin—CYP3A4—Metabolism—NAMPT—atherosclerosis	1.61e-05	0.00013	CbGpPWpGaD
Darifenacin—CHRM5—GPCR downstream signaling—AKT1—atherosclerosis	1.61e-05	0.00013	CbGpPWpGaD
Darifenacin—CYP3A4—Metabolism—LIPC—atherosclerosis	1.6e-05	0.00013	CbGpPWpGaD
Darifenacin—CYP3A4—Metabolism—APOC3—atherosclerosis	1.59e-05	0.000129	CbGpPWpGaD
Darifenacin—CHRM1—Signaling Pathways—PIK3CG—atherosclerosis	1.59e-05	0.000128	CbGpPWpGaD
Darifenacin—CYP3A4—Metabolism—LDLR—atherosclerosis	1.58e-05	0.000128	CbGpPWpGaD
Darifenacin—CHRM3—Signaling Pathways—PIK3CG—atherosclerosis	1.58e-05	0.000128	CbGpPWpGaD
Darifenacin—CHRM5—Signaling by GPCR—IL6—atherosclerosis	1.58e-05	0.000128	CbGpPWpGaD
Darifenacin—CHRM3—Metabolism—NOS3—atherosclerosis	1.57e-05	0.000127	CbGpPWpGaD
Darifenacin—CHRM4—Signaling Pathways—MMP9—atherosclerosis	1.57e-05	0.000127	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—PIK3CG—atherosclerosis	1.57e-05	0.000127	CbGpPWpGaD
Darifenacin—CYP2D6—Metabolism—APOB—atherosclerosis	1.57e-05	0.000127	CbGpPWpGaD
Darifenacin—CHRM4—Signaling Pathways—NFKB1—atherosclerosis	1.55e-05	0.000126	CbGpPWpGaD
Darifenacin—CYP3A4—Metabolism—CETP—atherosclerosis	1.55e-05	0.000125	CbGpPWpGaD
Darifenacin—CHRM4—Signaling Pathways—MAPK8—atherosclerosis	1.53e-05	0.000123	CbGpPWpGaD
Darifenacin—CYP2D6—Metabolism—GSTM1—atherosclerosis	1.53e-05	0.000123	CbGpPWpGaD
Darifenacin—CHRM4—Signaling by GPCR—AKT1—atherosclerosis	1.52e-05	0.000123	CbGpPWpGaD
Darifenacin—CHRM1—Signaling by GPCR—MAPK3—atherosclerosis	1.52e-05	0.000123	CbGpPWpGaD
Darifenacin—CHRM3—Signaling by GPCR—MAPK3—atherosclerosis	1.52e-05	0.000123	CbGpPWpGaD
Darifenacin—CHRM1—Signaling Pathways—INS—atherosclerosis	1.5e-05	0.000122	CbGpPWpGaD
Darifenacin—CHRM5—Signaling Pathways—MMP9—atherosclerosis	1.5e-05	0.000121	CbGpPWpGaD
Darifenacin—CHRM2—Signaling by GPCR—MAPK3—atherosclerosis	1.5e-05	0.000121	CbGpPWpGaD
Darifenacin—CHRM3—Signaling Pathways—INS—atherosclerosis	1.5e-05	0.000121	CbGpPWpGaD
Darifenacin—CYP2D6—Metabolism—LPL—atherosclerosis	1.5e-05	0.000121	CbGpPWpGaD
Darifenacin—CHRM5—Signaling Pathways—NFKB1—atherosclerosis	1.49e-05	0.00012	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—INS—atherosclerosis	1.48e-05	0.00012	CbGpPWpGaD
Darifenacin—CYP3A4—Metabolism—SCARB1—atherosclerosis	1.48e-05	0.00012	CbGpPWpGaD
Darifenacin—CHRM1—Signaling Pathways—CCL2—atherosclerosis	1.48e-05	0.00012	CbGpPWpGaD
Darifenacin—CHRM3—Signaling Pathways—CCL2—atherosclerosis	1.48e-05	0.000119	CbGpPWpGaD
Darifenacin—CHRM5—Signaling Pathways—MAPK8—atherosclerosis	1.46e-05	0.000118	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—CCL2—atherosclerosis	1.46e-05	0.000118	CbGpPWpGaD
Darifenacin—CYP2D6—Metabolism—GPX1—atherosclerosis	1.46e-05	0.000118	CbGpPWpGaD
Darifenacin—CHRM5—Signaling by GPCR—AKT1—atherosclerosis	1.46e-05	0.000118	CbGpPWpGaD
Darifenacin—CHRM1—Signaling Pathways—IGF1—atherosclerosis	1.45e-05	0.000118	CbGpPWpGaD
Darifenacin—CHRM3—Signaling Pathways—IGF1—atherosclerosis	1.45e-05	0.000117	CbGpPWpGaD
Darifenacin—CHRM3—Metabolism—PTGS2—atherosclerosis	1.44e-05	0.000116	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—IGF1—atherosclerosis	1.44e-05	0.000116	CbGpPWpGaD
Darifenacin—CYP2D6—Metabolism—CD36—atherosclerosis	1.42e-05	0.000115	CbGpPWpGaD
Darifenacin—CHRM4—Signaling Pathways—VEGFA—atherosclerosis	1.41e-05	0.000114	CbGpPWpGaD
Darifenacin—CYP3A4—Metabolism—HMGCR—atherosclerosis	1.4e-05	0.000113	CbGpPWpGaD
Darifenacin—CHRM4—Signaling Pathways—STAT3—atherosclerosis	1.4e-05	0.000113	CbGpPWpGaD
Darifenacin—CHRM1—Signaling Pathways—SERPINE1—atherosclerosis	1.38e-05	0.000112	CbGpPWpGaD
Darifenacin—CHRM3—Signaling Pathways—SERPINE1—atherosclerosis	1.38e-05	0.000111	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—SERPINE1—atherosclerosis	1.36e-05	0.00011	CbGpPWpGaD
Darifenacin—CHRM5—Signaling Pathways—VEGFA—atherosclerosis	1.35e-05	0.000109	CbGpPWpGaD
Darifenacin—CYP2D6—Metabolism—MTHFR—atherosclerosis	1.35e-05	0.000109	CbGpPWpGaD
Darifenacin—CHRM5—Signaling Pathways—STAT3—atherosclerosis	1.34e-05	0.000108	CbGpPWpGaD
Darifenacin—CHRM4—Signaling Pathways—MAPK3—atherosclerosis	1.33e-05	0.000108	CbGpPWpGaD
Darifenacin—CYP2D6—Metabolism—PPARA—atherosclerosis	1.32e-05	0.000107	CbGpPWpGaD
Darifenacin—CHRM1—Signaling Pathways—NOS3—atherosclerosis	1.32e-05	0.000107	CbGpPWpGaD
Darifenacin—CHRM3—Signaling Pathways—NOS3—atherosclerosis	1.31e-05	0.000106	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—NOS3—atherosclerosis	1.3e-05	0.000105	CbGpPWpGaD
Darifenacin—CHRM4—Signaling Pathways—TGFB1—atherosclerosis	1.29e-05	0.000105	CbGpPWpGaD
Darifenacin—CYP2D6—Metabolism—AGT—atherosclerosis	1.28e-05	0.000104	CbGpPWpGaD
Darifenacin—CHRM5—Signaling Pathways—MAPK3—atherosclerosis	1.28e-05	0.000103	CbGpPWpGaD
Darifenacin—CYP2D6—Metabolism—APOE—atherosclerosis	1.26e-05	0.000101	CbGpPWpGaD
Darifenacin—CYP3A4—Metabolism—ABCA1—atherosclerosis	1.25e-05	0.000101	CbGpPWpGaD
Darifenacin—CYP2D6—Metabolism—CAV1—atherosclerosis	1.24e-05	0.000101	CbGpPWpGaD
Darifenacin—CYP2D6—Metabolism—APOA1—atherosclerosis	1.24e-05	0.0001	CbGpPWpGaD
Darifenacin—CHRM5—Signaling Pathways—TGFB1—atherosclerosis	1.24e-05	0.0001	CbGpPWpGaD
Darifenacin—CHRM1—Signaling Pathways—CXCL8—atherosclerosis	1.17e-05	9.46e-05	CbGpPWpGaD
Darifenacin—CHRM3—Signaling Pathways—CXCL8—atherosclerosis	1.17e-05	9.43e-05	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—CXCL8—atherosclerosis	1.16e-05	9.34e-05	CbGpPWpGaD
Darifenacin—CYP2D6—Metabolism—PIK3CG—atherosclerosis	1.13e-05	9.15e-05	CbGpPWpGaD
Darifenacin—CHRM1—GPCR downstream signaling—AKT1—atherosclerosis	1.13e-05	9.14e-05	CbGpPWpGaD
Darifenacin—CHRM3—GPCR downstream signaling—AKT1—atherosclerosis	1.13e-05	9.11e-05	CbGpPWpGaD
Darifenacin—CHRM2—GPCR downstream signaling—AKT1—atherosclerosis	1.12e-05	9.02e-05	CbGpPWpGaD
Darifenacin—CHRM1—Signaling by GPCR—IL6—atherosclerosis	1.11e-05	8.99e-05	CbGpPWpGaD
Darifenacin—CHRM3—Signaling by GPCR—IL6—atherosclerosis	1.11e-05	8.96e-05	CbGpPWpGaD
Darifenacin—CHRM2—Signaling by GPCR—IL6—atherosclerosis	1.1e-05	8.88e-05	CbGpPWpGaD
Darifenacin—CYP2D6—Metabolism—PPARG—atherosclerosis	1.09e-05	8.84e-05	CbGpPWpGaD
Darifenacin—CYP2D6—Metabolism—INS—atherosclerosis	1.07e-05	8.67e-05	CbGpPWpGaD
Darifenacin—CYP3A4—Metabolism—HMOX1—atherosclerosis	1.07e-05	8.65e-05	CbGpPWpGaD
Darifenacin—CHRM1—Signaling Pathways—MMP9—atherosclerosis	1.06e-05	8.55e-05	CbGpPWpGaD
Darifenacin—CHRM3—Signaling Pathways—MMP9—atherosclerosis	1.05e-05	8.53e-05	CbGpPWpGaD
Darifenacin—CHRM1—Signaling Pathways—NFKB1—atherosclerosis	1.05e-05	8.46e-05	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—MMP9—atherosclerosis	1.04e-05	8.44e-05	CbGpPWpGaD
Darifenacin—CHRM3—Signaling Pathways—NFKB1—atherosclerosis	1.04e-05	8.44e-05	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—NFKB1—atherosclerosis	1.03e-05	8.35e-05	CbGpPWpGaD
Darifenacin—CHRM1—Signaling Pathways—MAPK8—atherosclerosis	1.03e-05	8.32e-05	CbGpPWpGaD
Darifenacin—CHRM1—Signaling by GPCR—AKT1—atherosclerosis	1.03e-05	8.3e-05	CbGpPWpGaD
Darifenacin—CHRM3—Signaling Pathways—MAPK8—atherosclerosis	1.03e-05	8.29e-05	CbGpPWpGaD
Darifenacin—CYP3A4—Metabolism—APOB—atherosclerosis	1.03e-05	8.29e-05	CbGpPWpGaD
Darifenacin—CHRM3—Signaling by GPCR—AKT1—atherosclerosis	1.02e-05	8.27e-05	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—MAPK8—atherosclerosis	1.02e-05	8.21e-05	CbGpPWpGaD
Darifenacin—CHRM2—Signaling by GPCR—AKT1—atherosclerosis	1.01e-05	8.19e-05	CbGpPWpGaD
Darifenacin—CYP3A4—Metabolism—GSTM1—atherosclerosis	9.97e-06	8.06e-05	CbGpPWpGaD
Darifenacin—CYP2D6—Metabolism—ALB—atherosclerosis	9.83e-06	7.94e-05	CbGpPWpGaD
Darifenacin—CYP3A4—Metabolism—LPL—atherosclerosis	9.79e-06	7.91e-05	CbGpPWpGaD
Darifenacin—CHRM4—Signaling Pathways—IL6—atherosclerosis	9.75e-06	7.88e-05	CbGpPWpGaD
Darifenacin—CYP3A4—Metabolism—GPX1—atherosclerosis	9.55e-06	7.72e-05	CbGpPWpGaD
Darifenacin—CHRM1—Signaling Pathways—VEGFA—atherosclerosis	9.5e-06	7.68e-05	CbGpPWpGaD
Darifenacin—CHRM3—Signaling Pathways—VEGFA—atherosclerosis	9.47e-06	7.66e-05	CbGpPWpGaD
Darifenacin—CHRM1—Signaling Pathways—STAT3—atherosclerosis	9.41e-06	7.61e-05	CbGpPWpGaD
Darifenacin—CYP2D6—Metabolism—NOS3—atherosclerosis	9.4e-06	7.6e-05	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—VEGFA—atherosclerosis	9.38e-06	7.58e-05	CbGpPWpGaD
Darifenacin—CHRM3—Signaling Pathways—STAT3—atherosclerosis	9.38e-06	7.58e-05	CbGpPWpGaD
Darifenacin—CHRM5—Signaling Pathways—IL6—atherosclerosis	9.34e-06	7.54e-05	CbGpPWpGaD
Darifenacin—CYP3A4—Metabolism—CD36—atherosclerosis	9.3e-06	7.52e-05	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—STAT3—atherosclerosis	9.29e-06	7.51e-05	CbGpPWpGaD
Darifenacin—CHRM4—Signaling Pathways—AKT1—atherosclerosis	8.99e-06	7.27e-05	CbGpPWpGaD
Darifenacin—CHRM1—Signaling Pathways—MAPK3—atherosclerosis	8.99e-06	7.27e-05	CbGpPWpGaD
Darifenacin—CHRM3—Signaling Pathways—MAPK3—atherosclerosis	8.96e-06	7.24e-05	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—MAPK3—atherosclerosis	8.87e-06	7.17e-05	CbGpPWpGaD
Darifenacin—CYP3A4—Metabolism—MTHFR—atherosclerosis	8.81e-06	7.12e-05	CbGpPWpGaD
Darifenacin—CHRM1—Signaling Pathways—TGFB1—atherosclerosis	8.72e-06	7.05e-05	CbGpPWpGaD
Darifenacin—CHRM3—Signaling Pathways—TGFB1—atherosclerosis	8.7e-06	7.03e-05	CbGpPWpGaD
Darifenacin—CYP3A4—Metabolism—PPARA—atherosclerosis	8.65e-06	6.99e-05	CbGpPWpGaD
Darifenacin—CHRM5—Signaling Pathways—AKT1—atherosclerosis	8.61e-06	6.96e-05	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—TGFB1—atherosclerosis	8.61e-06	6.96e-05	CbGpPWpGaD
Darifenacin—CYP2D6—Metabolism—PTGS2—atherosclerosis	8.6e-06	6.95e-05	CbGpPWpGaD
Darifenacin—CYP3A4—Metabolism—AGT—atherosclerosis	8.37e-06	6.77e-05	CbGpPWpGaD
Darifenacin—CYP3A4—Metabolism—APOE—atherosclerosis	8.21e-06	6.63e-05	CbGpPWpGaD
Darifenacin—CYP3A4—Metabolism—CAV1—atherosclerosis	8.13e-06	6.57e-05	CbGpPWpGaD
Darifenacin—CYP3A4—Metabolism—APOA1—atherosclerosis	8.11e-06	6.56e-05	CbGpPWpGaD
Darifenacin—CYP3A4—Metabolism—PIK3CG—atherosclerosis	7.41e-06	5.99e-05	CbGpPWpGaD
Darifenacin—CHRM3—Metabolism—AKT1—atherosclerosis	7.23e-06	5.84e-05	CbGpPWpGaD
Darifenacin—CYP3A4—Metabolism—PPARG—atherosclerosis	7.15e-06	5.78e-05	CbGpPWpGaD
Darifenacin—CYP3A4—Metabolism—INS—atherosclerosis	7.01e-06	5.67e-05	CbGpPWpGaD
Darifenacin—CHRM1—Signaling Pathways—IL6—atherosclerosis	6.57e-06	5.31e-05	CbGpPWpGaD
Darifenacin—CHRM3—Signaling Pathways—IL6—atherosclerosis	6.55e-06	5.3e-05	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—IL6—atherosclerosis	6.49e-06	5.24e-05	CbGpPWpGaD
Darifenacin—CYP3A4—Metabolism—ALB—atherosclerosis	6.43e-06	5.19e-05	CbGpPWpGaD
Darifenacin—CYP3A4—Metabolism—NOS3—atherosclerosis	6.15e-06	4.97e-05	CbGpPWpGaD
Darifenacin—CHRM1—Signaling Pathways—AKT1—atherosclerosis	6.06e-06	4.9e-05	CbGpPWpGaD
Darifenacin—CHRM3—Signaling Pathways—AKT1—atherosclerosis	6.04e-06	4.89e-05	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—AKT1—atherosclerosis	5.99e-06	4.84e-05	CbGpPWpGaD
Darifenacin—CYP3A4—Metabolism—PTGS2—atherosclerosis	5.62e-06	4.54e-05	CbGpPWpGaD
Darifenacin—CYP2D6—Metabolism—AKT1—atherosclerosis	4.32e-06	3.49e-05	CbGpPWpGaD
Darifenacin—CYP3A4—Metabolism—AKT1—atherosclerosis	2.83e-06	2.28e-05	CbGpPWpGaD
